Pomerantz LLP is investigating claims on behalf of investors of Acadia Pharmaceuticals Inc. ("Acadia" or the "Company"). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
The investigation concerns whether Acadia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On April 9, 2018, CNN reported that Nuplazid, Acadia's Parkinson's disease psychosis treatment, has been associated with more than 700 deaths, and that adverse event reports concerning the drug link it to additional life-threatening incidents, falls, insomnia, nausea, and fatigue.